NASDAQ:ATRCAtriCure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AtriCure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $41.63 +0.82 (+2.01 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$40.37Now: $41.63▼$42.0250-Day Range$40.81MA: $44.67▼$46.9152-Week Range$22.57Now: $41.63▼$51.76Volume308,380 shsAverage Volume319,929 shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.78, AtriCure has a potential upside of 17.2% from its current price of $41.63.Amount of Analyst CoverageAtriCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesAtriCure has received 485 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtriCure has received 354 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtriCure has received 57.81% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote “Outperform” if you believe ATRC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,453,400.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of AtriCure is held by insiders.Percentage Held by Institutions89.94% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($1.30) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -32.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -32.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC Previous Symbol CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone513-755-4100Debt Debt-to-Equity Ratio0.16 Current Ratio7.67 Quick Ratio6.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$230.81 million Price / Sales8.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book6.66Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-35,190,000.00 Net Margins-23.64% Return on Equity-19.55% Return on Assets-9.56%Miscellaneous Employees620 Outstanding Shares44,930,000Market Cap$1.87 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $41.63 +0.82 (+2.01 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATRC News and Ratings via Email Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. AtriCure (NASDAQ:ATRC) Frequently Asked Questions How has AtriCure's stock been impacted by COVID-19 (Coronavirus)? AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC shares have increased by 18.0% and is now trading at $41.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AtriCure? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure. When is AtriCure's next earnings date? AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for AtriCure. How were AtriCure's earnings last quarter? AtriCure Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, July, 28th. The medical device company reported ($0.38) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.21. The medical device company had revenue of $40.82 million for the quarter, compared to analysts' expectations of $36.07 million. AtriCure had a negative net margin of 23.64% and a negative return on equity of 19.55%. AtriCure's revenue for the quarter was down 30.7% on a year-over-year basis. During the same period last year, the firm posted ($0.17) earnings per share. View AtriCure's earnings history. What price target have analysts set for ATRC? 9 brokers have issued 12 month price targets for AtriCure's shares. Their forecasts range from $30.00 to $60.00. On average, they expect AtriCure's stock price to reach $48.78 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price. View analysts' price targets for AtriCure. Has AtriCure been receiving favorable news coverage? Media coverage about ATRC stock has trended somewhat negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AtriCure earned a news impact score of -1.7 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news about AtriCure. Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR) and Steris (STE). View all competitors. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), Allergan (AGN), CVS Health (CVS), Walt Disney (DIS) and Intel (INTC). Who are AtriCure's key executives? AtriCure's management team includes the following people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)Mr. Douglas J. Seith, Chief Operating Officer (Age 53)Mr. Salvatore Privitera, Chief Technology Officer (Age 52)Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41) What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." Who are AtriCure's major shareholders? AtriCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (1.30%), Emerald Mutual Fund Advisers Trust (1.19%), Peregrine Capital Management LLC (0.80%), First Trust Advisors LP (0.13%), Foundry Partners LLC (0.09%) and Dupont Capital Management Corp (0.08%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View institutional ownership trends for AtriCure. Which major investors are selling AtriCure stock? ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Dupont Capital Management Corp, Chartwell Investment Partners LLC, Strs Ohio, Foundry Partners LLC, and MAI Capital Management. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, and Michael H Carrel. View insider buying and selling activity for AtriCure. Which major investors are buying AtriCure stock? ATRC stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Mackay Shields LLC, Brinker Capital Inc., First Trust Advisors LP, Envestnet Asset Management Inc., Clear Creek Financial Management LLC, and SG Americas Securities LLC. View insider buying and selling activity for AtriCure. How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $41.63. How big of a company is AtriCure? AtriCure has a market capitalization of $1.87 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe. What is AtriCure's official website? The official website for AtriCure is www.atricure.com. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100. This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
